AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie ozurdex (dexamethasone intravitreal implant) — U.S. net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
124
Period ended Dec 31, 2025
Change on a year earlier
-10.1%
138 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ozurdex (dexamethasone intravitreal implant) — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 124 | -10.1% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 138 | -3.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 143 | +2.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 139 | +6.9% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 130 | – | Form 10-K (filed 2024-02-20) ↗ |
Breakdown
What makes up ozurdex (dexamethasone intravitreal implant) — u.s. net revenues ($m)
Cite this data
StockData. (2026). AbbVie Ozurdex (dexamethasone intravitreal implant) — U.S. net revenues ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ozurdex_us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.